Nebivolol Teva (Nebivolol Hydrochloride)

• Nebivolol is a selective β1‑adrenergic blocker indicated for the management of hypertension.
• Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular outcomes.
• Chronic heart failure: lowers mortality and hospitalization rates by improving cardiac function.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, which reduces cardiac output. Concurrently, it stimulates endothelial nitric oxide synthase, leading to nitric oxide‑mediated vasodilation and further lowering of peripheral vascular resistance, thereby contributing to blood pressure reduction.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or general tiredness.
• Nasal congestion or rhinorrhea.
• Gastrointestinal discomfort, such as nausea.
• Insomnia or sleep disturbances.

Serious or Rare Side Effects

• Bradycardia: markedly reduced heart rate requiring medical attention.
• Severe hypotension: sudden drop in blood pressure leading to fainting.
• Cardiac conduction abnormalities, including heart block.
• Acute bronchospasm in susceptible individuals.
• Anaphylactic or severe allergic reactions.

• Nebivolol should be used with caution in specific clinical situations.
• Monitor blood pressure: ensure adequate control without excessive lowering.
• Assess cardiac function: evaluate heart rate and rhythm regularly.
• Use cautiously in asthma or COPD: beta‑blockade may exacerbate bronchospasm.
• Avoid abrupt discontinuation: taper dose to prevent rebound hypertension.
• Adjust in hepatic impairment: consider dose reduction if liver function is compromised.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several medication classes; awareness of major and moderate interactions helps optimize therapy.

Major Interactions (Avoid)

• Combined use with other beta‑blockers: may cause excessive bradycardia.
• Non‑selective beta‑blockers (e.g., propranolol): increased risk of cardiac depression.
• Calcium channel blockers verapamil or diltiazem: can potentiate negative inotropic effects.
• Strong CYP2D6 inhibitors (e.g., quinidine, paroxetine): raise nebivolol plasma levels.
• Antihypertensive agents causing profound hypotension.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive effect.
• ACE inhibitors or ARBs: monitor for additive blood pressure reduction.
• NSAIDs: may attenuate antihypertensive response.
• Antidiabetic drugs: monitor blood glucose as beta‑blockade can mask hypoglycemia.
• Other vasodilators: watch for excessive vasodilation.